Hovnanian Exits the S&P Top 10
On Dec. 5, Standard & Poor's equity research group made a change to the S&P Top 10 portfolio -- those issues it considers to be the best candidates for capital gains over the next 6 to 12 months. Biotech outfit IDEC Pharmaceuticals (IDPH ) will replace homebuilder Hovnanian (HOV ).
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.